If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGWP.L Regulatory News (GWP)

  • There is currently no data for GWP

Director/PDMR Shareholding

21 Dec 2015 18:22

RNS Number : 8050J
GW Pharmaceuticals PLC
21 December 2015
 



GW Pharmaceuticals PLC Director/PDMR Shareholding

21 December 2015

 

GW Pharmaceuticals PLC ("GW Pharmaceuticals" or the "Company")

NOTIFICATION OF INTERESTS OF DIRECTORS AND CONNECTED PERSONS

 

Cambridge, UK, 21 December 2015: GW Pharmaceuticals (AIM: GWP, NASDAQ:GWPH) hereby provides notification that the Company has been notified of the following series of transactions in the shares of GW Pharmaceuticals plc.

 

On 18 December 2015 the Company was notified that on 17 December 2015 Mr Cabot Brown, a non-executive Director of the Company, purchased 600 American Depository Shares, or ADS (equivalent to 7,200 ordinary 0.1 pence shares) of GW Pharmaceuticals plc, at a price of $68.864 per ADS (equivalent to 384 pence per share).

 

Following this notification Mr Brown's interest in the shares of GW Pharmaceuticals plc is 7,200 ordinary 0.1 pence shares (equivalent to 600 ADSs), representing less than 0.1% of the Company's current issued share capital.

 

On 18 December 2015 Mr. Chris Tovey, a Director and Chief Operating Officer of the Company, exercised options to acquire 24,000 ordinary 0.1 pence shares (equivalent to 2,000 ADSs) of GW Pharmaceuticals plc. These options had an exercise price of 0.1 pence per share. The Company has been notified that on 18 December 2015 these shares, representing less than 0.1% of shares in issue, were converted to 2,000 ADSs and immediately sold at an average price of $67.6275 per ADS (equivalent to 378 pence per share).

 

Following these transactions, Mr. Tovey's beneficial interested in the Company's ordinary 0.1 pence shares is 2,500 shares, representing less than 0.1% of the Company's current issued share capital.

 

On 18 December 2015 Dr. Geoffrey Guy, a Director and Chairman of the Company, exercised options to acquire 1,369,848 ordinary 0.1 pence shares (equivalent to 114,154 ADSs) of GW Pharmaceuticals plc. These options had a weighted average exercise price of 41 pence per ordinary 0.1 pence share. The Company has been notified that (1) on 18 December 2015, 1,065,936 of these shares were converted to 88,828 ADSs and immediately sold at an average price of $67.50 per ADS (equivalent to 377 pence per share) and (2) earlier today a further 10,309 ADSs (equivalent to 123,708 ordinary 0.1 pence shares) were sold at an average price of $67.32 per ADS (equivalent to 376 pence per share). Exercise of these options results in an immediate UK income tax liability for Dr. Guy necessitating the immediate sale of a significant number of the resulting shares. In addition, we have been notified that earlier today 6,000 ordinary 0.1 pence shares held by Dr Guy's personal pension scheme were sold at an average price of 366 pence per share.

 

Following these transactions, Dr. Guy's notifiable interest in the ordinary 0.1 pence shares of the Company has increased by 174,204 shares to 14,297,852 shares, representing 5.4% of the Company's current issued share capital.

 

The total number of shares outstanding in the Company is 262,574,021 ordinary 0.1 pence shares.

 

For further information, please contact:

 

GW Pharmaceuticals plc

Adam George, Company Secretary

+44 (0)1980 557 000

Peel Hunt LLP (UK NOMAD)

James Steel

+44 20 7418 8900

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSLLFFTFLLLFIE
Date   Source Headline
27th Jan 20157:01 amRNSNotice of Results
9th Jan 20154:24 pmRNSBlock Listing Application
8th Jan 201512:00 pmRNSUpdate on Epidiolex Program
8th Jan 201512:00 pmRNSResults in Sativex Phase 3 Cancer Pain Trial
22nd Dec 20147:00 amRNSGW Added to NASDAQ Biotechnology Index
17th Dec 20146:16 pmRNSPublication of UK Annual Report and Accounts
17th Dec 20144:49 pmRNSDirector/PDMR Shareholding
3rd Dec 20148:22 amRNSHolding(s) in Company
2nd Dec 201412:00 pmRNSFinal Results
26th Nov 20147:00 amRNSGW Presents at Piper Jaffray Healthcare Conference
24th Nov 20147:00 amRNSNotice of Results
17th Nov 20143:00 pmRNSPresenting at Jefferies 2014 Healthcare Conference
30th Oct 20147:00 amRNSPhase 2/3 Trial of Epidiolex in Dravet Syndrome
22nd Oct 20147:00 amRNSEpidiolex Orphan Designation from EMA
14th Oct 201412:00 pmRNSResults of Phase 2a Ulcerative Colitis Trial
14th Oct 201412:00 pmRNSNew Physician Reports of Epidiolex Treatment
7th Oct 20149:45 amRNSAdditional Listing
29th Sep 20141:00 pmRNSGW Research and Development Day Details
24th Sep 20147:00 amRNSPresenting at Leerink Rare Disease Roundtable 2014
29th Aug 201412:20 pmRNSDirector/PDMR Shareholding
28th Aug 20147:00 amRNSPresenting at Upcoming Investor Conferences
18th Aug 201411:19 amRNSBlocklisting Interim Review
12th Aug 20144:32 pmRNSGrant of Options
6th Aug 20147:00 amRNSThird Quarter Financial Results
30th Jul 20147:00 amRNSNotice of Results
8th Jul 201410:18 amRNSHolding(s) in Company
30th Jun 20145:15 pmRNSHolding(s) in Company
30th Jun 20145:12 pmRNSHolding(s) in Company
30th Jun 20142:11 pmRNSHolding(s) in Company
25th Jun 20144:16 pmRNSClosing of U.S. Public Offering of ADSs on NASDAQ
24th Jun 20149:18 amRNSExercise of Underwriters' Option to Purchase ADSs
19th Jun 20147:00 amRNSPricing of U.S. Public Offering of ADSs
18th Jun 20147:00 amRNSProposed Public Offering of ADSs
17th Jun 201412:00 pmRNSEpidiolex IND Data
9th Jun 201412:34 pmRNSBlock Listing Application
6th Jun 20147:00 amRNSEpidiolex Fast Track Designation - Dravet Syndrome
29th May 20143:11 pmRNSHolding(s) in Company
8th May 20145:00 pmRNSPresenting at BAML 2014 Health Care Conference
7th May 20147:02 amRNSHalf Yearly Report
7th May 20147:00 amRNSIND for Epidiolex Ph 2/3 Trial in Dravet Syndrome
6th May 20145:54 pmRNSHolding(s) in Company
6th May 20147:01 amRNSAppointment of VP, Clinical Science
29th Apr 20145:30 pmRNSNotice of Results
28th Apr 20141:46 pmRNSHolding(s) in Company
28th Apr 20147:00 amRNSSativex FDA Fast Track Designation in Cancer Pain
19th Mar 20143:24 pmRNSHolding(s) in Company
17th Mar 20147:00 amRNSUpdate on Cannabinoid Pipeline
11th Mar 20142:34 pmRNSAnnual General Meeting
28th Feb 20141:00 pmRNSFDA Orphan Drug Designation received for Epidiolex
27th Feb 20147:00 amRNSGW to Present at Cowen Health Care Conference

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.